https://european-biotechnology.net/wp-content/uploads/2026/01/tq-therapeutics-team-v2-device-web.jpeg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-14 14:13:002026-01-14 17:02:03Faster to the bedside: Collaboration in cell therapy of Fresenius Kabi and TQ Therapeutics
https://european-biotechnology.net/wp-content/uploads/2026/01/Biontech-Geba__ude.jpg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-13 11:17:222026-01-13 11:17:222026: A year of reckoning for BioNTech
https://european-biotechnology.net/wp-content/uploads/2026/01/towfiqu-barbhuiya-joqWSI9u_XM-unsplash-1030x687-1.jpg6871030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-12 15:13:342026-01-12 15:13:34bit.bio closes a $50 million series C round after its 2025 restructuring
https://european-biotechnology.net/wp-content/uploads/2026/01/roche-site-basel_official-web312708.jpeg540960Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-12 11:29:522026-01-12 17:02:02Second time around: Roche’s return to MediLink underlines the value of the first deal
https://european-biotechnology.net/wp-content/uploads/2026/01/Bayer_Pharmaceuticals_in_Berlin-1030x678-1.jpg6781030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-09 15:39:082026-01-09 17:32:02Better late than never: Bayer eyes a slice of the mRNA vaccine pie
https://european-biotechnology.net/wp-content/uploads/2026/01/ferdinand-stohr-PeFk7fzxTdk-unsplash-1030x665-1.jpg6651030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2026-01-09 12:20:472026-01-09 12:20:47French investor Andera makes a $227m bet on U.S. obesity and asthma innovation
